An itching drug that was a key part of the merger of Menlo Therapeutics and Foamix Pharmaceuticals has failed two late-stage studies, leading to a halt on further development of the compound.
The Menlo (NASDAQ: MNLO) drug, serlopitant, was being... Read more »
GlaxoSmithKline has agreed to invest $250 million in infectious disease specialist Vir Biotechnology to launch a COVID-19 R&D alliance that the companies say could advance two experimental therapies to clinical testing this summer.
The partnership will leverage antibody technology from Vir... Read more »
Based on the latest news and analysis, as well as conversations from industry experts during the Combatting Coronavirus live panel at BIO-Europe Spring®, Xconomy’s free special report delivers the latest COVID-19 news from the frontlines as top biotech and investment players... Read more »
The coronavirus pandemic has shaken the global economy, but three life sciences venture capital firms this week announced new funds totaling nearly $3 billion.
ARCH Venture Partners led the pack, adding two funds totaling $1.46 billion to its war chest. Flagship... Read more »
Flagship Pioneering founder and CEO Noubar Afeyan didn’t know a global pandemic was in the cards for 2020 when he and his team laid out three new thematic areas of focus for the company last fall.
One proved eerily prescient: The... Read more »
Parkinson’s disease patients experience progressive breakdown of their neurons, cells essential to movement and mental function. Aspen Neuroscience, a biotech working to develop a therapy that would reprogram those patients’ own living cells in ways that would allow the cells to... Read more »
Pandion Therapeutics emerged in 2018 aiming to reach clinic trials in two years testing its biologic drugs in autoimmune and inflammatory disorders. The company now has $80 million to support a lead program in early-stage testing and a pipeline of potential... Read more »
Finding and enrolling patients for clinical trials is always challenging. The coronavirus pandemic has made it nearly impossible.
Fallout from the spread of COVID-19 infections led several companies to declare this week that they would stop enrolling patients in clinical trials... Read more »
Two companies working on treatments for rare genetic lung diseases have combined efforts and raised $80 million to bring into human testing next year two investigational treatments that use types of RNA to tweak mutated proteins.
Dallas company ReCode Therapeutics and... Read more »
Future improvements in cancer care are most likely to stem from combinations therapies and data-driven prevention efforts, as well as breakthrough drugs.
That’s the message life sciences experts shared this week during a webcast on the topic of “oncology’s next decade”... Read more »
CytomX Therapeutics is teaming up with Astellas Pharma in a research and development alliance focused on developing new cancer immunotherapies based on its antibody technology.
Under deal terms announced late Monday, Astellas is paying CytomX (NASDAQ: CTMX) $80 million up... Read more »
Aimmune Therapeutics Inc. is navigating a host of new challenges as it launches Palforzia, the first peanut allergy immunotherapy to be approved by the US Food and Drug Administration. Most notably, it must get physician practices and individual allergists certified to administer... Read more »
The past week brought a sea change in many of our daily lives as the impact of the continued spread of the novel coronavirus altered how we work and play as communities around the world attempt to slow its spread.
Xconomy,... Read more »
Eureka Therapeutics, which has been developing methods to facilitate the development of cell therapies that can treat solid cancers, has raised $45 million to prove out its technologies in the clinic.
To enhance its chances of success, the Emeryville, CA-based company... Read more »
The following sponsored content was submitted by commercial real estate brokerage firm Hughes Marino:
The story of the “canary in the coal mine” is an advanced warning of danger. The metaphor originates from when miners used to carry caged canaries... Read more »
The financial markets are tumbling, event cancellations are mounting, and sports leagues are suspending their seasons. March Madness is in full swing but not in any way that people wanted or expected.
The World Health Organization this week... Read more »
Reuse and recycle is more than an environmental slogan. It’s also a succinct description of how cells deal with old or damaged proteins. Kymera Therapeutics is developing drugs that use this cyclical cellular process to treat disease, and it has raised... Read more »
Last month, Gilead Sciences CEO Daniel O’Day announced plans to introduce 10 “transformative medicines” over the next 10 years. Acquisitions would help meet that ambitious goal, and this week Gilead announced one of them: a nearly $5 billion deal for cancer... Read more »
Culture Biosciences, a contract development and manufacturing organization, has added new funding to increase bioreactor capacity and create additional monitoring software.
The San Francisco startup announced the completion of a $15 million Series A financing round this week, bringing aboard fresh... Read more »
Cell therapies have helped treat some blood cancers, but toxic side effects are one limitation preventing their use in solid tumors.
Amunix has, since its 2006 launch, licensed to biopharmas technology developed by company co-founder Volker Schellenberger to extend the half-life... Read more »
When Novartis signed on as a partner to Pliant Therapeutics last fall, it also agreed to eventually take an equity stake in the smaller biotech. The Swiss pharmaceutical giant made good on that commitment Tuesday, leading a $100 million investment.... Read more »
The nomination period for the 2020 National Xconomy Awards is now open. The awards are open to individuals, companies, and organizations working across the life sciences in the United States, and feature leaders in the biotech industry, medicine, academia, digital health,... Read more »
Sponsored · Whitepaper
A growing nationalist and protectionist mindset around the world is creating a fresh set of challenges for global businesses
IDA Ireland
Sponsored · Whitepaper
New approaches & tech are on the horizon that could change how researchers and clinicians approach brain and neurological disorders
Sponsored · Special Report
Hyperinflation in rents is over
Hughes Marino
